Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update

Robert G MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Type 2 diabetes is a progressive disease associated with high levels of morbidity and mortality and for which there is both a large and growing prevalence worldwi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Robert G Moses
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/21f59617a0f946468d362614b2276918
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:21f59617a0f946468d362614b2276918
record_format	dspace
spelling	oai:doaj.org-article:21f59617a0f946468d362614b22769182021-12-02T07:38:54ZRepaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update1178-7007https://doaj.org/article/21f59617a0f946468d362614b22769182010-05-01T00:00:00Zhttp://www.dovepress.com/repaglinidemetformin-fixed-dose-combination-to-improve-glycemic-contro-a4411https://doaj.org/toc/1178-7007Robert G MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Type 2 diabetes is a progressive disease associated with high levels of morbidity and mortality and for which there is both a large and growing prevalence worldwide. Lifestyle advice plus metformin is commonly recommended initially to manage hyperglycemia and to minimize the risk of vascular complications. However, additional agents are required when glycemic targets cannot be achieved or maintained due to the progressive nature of the disease. Repaglinide/metformin fixed-dose combination (FDC) therapy (PrandiMet&reg;; Novo Nordisk, Bagsv&aelig;rd, Denmark) has been approved for use in the USA. This FDC is a rational second-line therapy given the complementary mechanisms of action of the components. Repaglinide is a rapidly absorbed, short-acting insulin secretagogue targeting postprandial glucose excursions; metformin is an insulin sensitizer with a longer duration of action that principally regulates basal glucose levels. A pivotal, 26-week, randomized study with repaglinide/metformin FDC therapy has been conducted in patients experiencing suboptimal control with previous oral antidiabetes therapy. Repaglinide/metformin FDC improved glycemic control and weight neutrality without adverse effects on lipid profiles. There were no major hypoglycemic episodes and patients expressed greater satisfaction with repaglinide/metformin FDC than previous treatments. Repaglinide/metformin FDC is expected to be more convenient than individual tablets for patients taking repaglinide and metformin in loose combination, and it is expected to improve glycemic control in patients for whom meglitinide or metformin monotherapies provide inadequate control.Keywords: type 2 diabetes, metformin, repaglinide, PrandiMet&reg;, fixed-dose combination Robert G MosesDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 145-154 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Robert G Moses Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
description	Robert G MosesClinical Trials and Research Unit, South East Sydney and Illawarra Area Health Service, New South Wales, AustraliaAbstract: Type 2 diabetes is a progressive disease associated with high levels of morbidity and mortality and for which there is both a large and growing prevalence worldwide. Lifestyle advice plus metformin is commonly recommended initially to manage hyperglycemia and to minimize the risk of vascular complications. However, additional agents are required when glycemic targets cannot be achieved or maintained due to the progressive nature of the disease. Repaglinide/metformin fixed-dose combination (FDC) therapy (PrandiMet&reg;; Novo Nordisk, Bagsv&aelig;rd, Denmark) has been approved for use in the USA. This FDC is a rational second-line therapy given the complementary mechanisms of action of the components. Repaglinide is a rapidly absorbed, short-acting insulin secretagogue targeting postprandial glucose excursions; metformin is an insulin sensitizer with a longer duration of action that principally regulates basal glucose levels. A pivotal, 26-week, randomized study with repaglinide/metformin FDC therapy has been conducted in patients experiencing suboptimal control with previous oral antidiabetes therapy. Repaglinide/metformin FDC improved glycemic control and weight neutrality without adverse effects on lipid profiles. There were no major hypoglycemic episodes and patients expressed greater satisfaction with repaglinide/metformin FDC than previous treatments. Repaglinide/metformin FDC is expected to be more convenient than individual tablets for patients taking repaglinide and metformin in loose combination, and it is expected to improve glycemic control in patients for whom meglitinide or metformin monotherapies provide inadequate control.Keywords: type 2 diabetes, metformin, repaglinide, PrandiMet&reg;, fixed-dose combination
format	article
author	Robert G Moses
author_facet	Robert G Moses
author_sort	Robert G Moses
title	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_short	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_full	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_fullStr	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_full_unstemmed	Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
title_sort	repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/21f59617a0f946468d362614b2276918
work_keys_str_mv	AT robertgmoses repaglinidemetforminfixeddosecombinationtoimproveglycemiccontrolinpatientswithtype2diabetesanupdate
_version_	1718399268657561600

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update

Ejemplares similares